These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 27841045)

  • 1. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).
    Ojha R; Singh J; Ojha A; Singh H; Sharma S; Nepali K
    Expert Opin Ther Pat; 2017 Mar; 27(3):311-345. PubMed ID: 27841045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).
    Singh JV; Bedi PMS; Singh H; Sharma S
    Expert Opin Ther Pat; 2020 Oct; 30(10):769-780. PubMed ID: 32797760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Design, synthesis and biological evaluation of oxadiazole derivatives as xanthine oxidase inhibitors].
    Yan DA; Zhang L; Tian JY; Ye F; Xiao ZY
    Yao Xue Xue Bao; 2016 Jun; 51(6):954-60. PubMed ID: 29879350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
    Yoon IS; Park DH; Ki SH; Cho SS
    J Pharm Pharmacol; 2016 Dec; 68(12):1597-1603. PubMed ID: 27696407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
    Lü JM; Yao Q; Chen C
    Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action.
    Ferrari FC; Lemos Lima Rde C; Schimith Ferraz Filha Z; Barros CH; de Paula Michel Araújo MC; Antunes Saúde-Guimarães D
    J Ethnopharmacol; 2016 Mar; 180():37-42. PubMed ID: 26778678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xanthine oxidase inhibitors: a patent survey.
    Kumar R; Darpan ; Sharma S; Singh R
    Expert Opin Ther Pat; 2011 Jul; 21(7):1071-108. PubMed ID: 21510722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
    Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
    Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization and xanthine oxidase inhibitory potential of Zanthoxylum armatum fruits.
    Ranjana ; Nooreen Z; Bushra U; Jyotshna ; Bawankule DU; Shanker K; Ahmad A; Tandon S
    J Ethnopharmacol; 2019 Feb; 230():1-8. PubMed ID: 30342965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
    Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
    Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease?
    Orhan IE; Deniz FSS
    Curr Pharm Des; 2021; 27(2):143-158. PubMed ID: 32723252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia.
    Xie Z; Luo X; Zou Z; Zhang X; Huang F; Li R; Liao S; Liu Y
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3602-3606. PubMed ID: 28655421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout.
    Ahmad NS; Farman M; Najmi MH; Mian KB; Hasan A
    J Ethnopharmacol; 2008 May; 117(3):478-82. PubMed ID: 18420362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.